A systematic comparison of hepatobiliary adverse drug reactions in FDA and EMA drug labeling reveals discrepancies

FDA, 2018, 2018 FDA, 2013 Watson, 2009, The New Food and Drug Administration Drug Package Insert: implications for patient safety and clinical care, Anesthesia Analgesia, 108, 211, 10.1213/ane.0b013e31818c1b27 McMahon, 2014, The package insert: who writes it and why, what are its implications, and how well does medical school explain it?, J Psychiatric Pract, 20, 284, 10.1097/01.pra.0000452565.83039.20 FDA, 2011 EMA, 2009 Kashoki, 2020, A comparison of EMA and FDA decisions for new drug marketing applications 2014–2016: concordance, discordance, and why, Clin Pharmacol Ther, 107, 195, 10.1002/cpt.1565 Bjornsson, 2015, Discrepancies in liver disease labeling in the package inserts of commonly prescribed medications, Gastroenterology, 148, 269, 10.1053/j.gastro.2014.12.007 DeMuro, 2013, Assessment of PRO label claims granted by the FDA as compared to the EMA (2006–2010), Value Health, 16, 1150, 10.1016/j.jval.2013.08.2293 Nieminen, 2005, Differences in product information of biopharmaceuticals in the EU and the USA: implications for product development, Eur J Pharm Biopharm, 60, 319, 10.1016/j.ejpb.2005.01.013 FDA, 2020 Ernst, 2001, Drug-related morbidity and mortality: updating the cost-of-illness model, J Am Pharm Assoc, 41, 192 Johnson, 1997, Drug-related morbidity and mortality and the economic impact of pharmaceutical care, Am J Health-Syst Pharm, 54, 554, 10.1093/ajhp/54.5.554 Lazarou, 1998, Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies, JAMA, 279, 1200, 10.1001/jama.279.15.1200 Murphy, 2006, ‘Black box’ 101: how the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk, J Allergy Clin Immunol, 117, 34, 10.1016/j.jaci.2005.10.031 Chen, 2016, DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans, Drug Discovery Today, 21, 648, 10.1016/j.drudis.2016.02.015 Suzuki, 2015, Comedications alter drug-induced liver injury reporting frequency: data mining in the WHO VigiBase™, Regulat Toxicol Pharmacol: RTP, 72, 481, 10.1016/j.yrtph.2015.05.004 Hoyumpa, 1982, Major drug interactions: effect of liver disease, alcohol, and malnutrition, Annu Rev Med, 33, 113, 10.1146/annurev.me.33.020182.000553 Franz, 2013, Dose adjustment in patients with liver cirrhosis: impact on adverse drug reactions and hospitalizations, Eur J Clin Pharmacol, 69, 1565, 10.1007/s00228-013-1502-z Frye, 2006, Liver disease selectively modulates cytochrome P450–mediated metabolism, Clin Pharmacol Ther, 80, 235, 10.1016/j.clpt.2006.05.006 Chalasani, 2016, Drug-induced liver injury in patients with preexisting chronic liver disease in drug development: how to identify and manage?, Gastroenterology, 151, 1046, 10.1053/j.gastro.2016.10.010 Chalasani, 2010, Risk factors for idiosyncratic drug-induced liver injury, Gastroenterology, 138, 2246, 10.1053/j.gastro.2010.04.001 Lewis, 2002, The rational use of potentially hepatotoxic medications in patients with underlying liver disease, Expert Opin Drug Saf, 1, 159, 10.1517/14740338.1.2.159 Russo, 2004, Are patients with elevated liver tests at increased risk of drug-induced liver injury?, Gastroenterology, 126, 1477, 10.1053/j.gastro.2004.03.030 Fontana, 2009, Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct, Drug Saf, 32, 55, 10.2165/00002018-200932010-00005 Chen, 2011, FDA-approved drug labeling for the study of drug-induced liver injury, Drug Discovery Today, 16, 697, 10.1016/j.drudis.2011.05.007 Björnsson, 2016, Categorization of drugs implicated in causing liver injury: Critical assessment based on published case reports, Hepatology, 63, 590, 10.1002/hep.28323 Liang, 2002, FDA use of the black box warning: time for reevaluation as a safety tool, J Clin Anesth, 14, 561, 10.1016/S0952-8180(02)00444-0 Yarrington, 2019, Impact of FDA black box warning on fluoroquinolone and alternative antibiotic use in southeastern US hospitals, Infect Control Hosp Epidemiol, 40, 1297, 10.1017/ice.2019.247 McCormack, 2005, Metformin’s contraindications should be contraindicated, Can Med Assoc J, 173, 502, 10.1503/cmaj.045292 Zaremba, 2019, Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?, J ImmunoTher Cancer, 7, 10.1186/s40425-019-0626-9 Björnsson, 2016, Hepatotoxicity by drugs: the most common implicated agents, Int J Mol Sci, 17, 224, 10.3390/ijms17020224 Chalasani, 2015, Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study, Gastroenterology, 148, 1340, 10.1053/j.gastro.2015.03.006 Suzuki, 2010, Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBaseTM, Drug Saf, 33, 503, 10.2165/11535340-000000000-00000 Rockey, 2010, Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method, Hepatology, 51, 2117, 10.1002/hep.23577 Hey-Hadavi, 2021, Overview of causality assessment for drug-induced liver injury (DILI) in clinical trials, Drug Saf, 44, 619, 10.1007/s40264-021-01051-5 Hazell, 2006, Under-reporting of adverse drug reactions: a systematic review, Drug Saf, 29, 385, 10.2165/00002018-200629050-00003 Alatawi, 2017, Empirical estimation of under-reporting in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS), Expert Opin Drug Saf, 16, 761, 10.1080/14740338.2017.1323867 Tomlin, 2012, Methods for retrospective detection of drug safety signals and adverse events in electronic general practice records, Drug Saf, 35, 733, 10.1007/BF03261970